// App-Quantinova.ai

: Pharmacogenetic Study of Ibrutinib Toxicity in Chronic Lymphocytic Leukemia Patients

Researchers

Presenter

  • Jorge Labrador

Principal Investigators

  • Maria Victoria Cuevas

  • Cristina Alonso-Madrigal

  • Pablo Zubiaur

  • Raul Azibeiro

  • Beatriz Cuevas

  • Rodolfo Alvarez

  • Francisco Javier Diaz-Galvez

  • Tomas Jose Gonzalez-Lopez

  • Raquel Alcaraz

  • Gina Paola Mejía-Abril

  • Javier Loscertales

  • Francisco Abad

  • Miriam Saiz-Rodríguez

Medical Centers

  • Department of Hematology, Hospital Universitario de Burgos, Burgos, Spain

  • Hematology Department, Hospital Universitario de Burgos, Burgos, Spain

  • Hospital Universitario de Burgos, Burgos, Spain

  • Hospital Universitario de la Princesa, Madrid, Spain

  • Research Unit, FBIS-Hospital Universitario de Burgos, Burgos, Spain

  • Facultad de Ciencias de la Salud, Universidad Isabel I, Burgos, Spain

  • University Hospital of La Princesa, Madrid, Spain

  • Hospital Santiago Apóstol, Miranda de Ebro, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • ATP Binding Cassette Transporter B1

  • ATP-binding cassette super-family G member 2

  • Cytochrome P450 Family 3 Subfamily A Member 4

Drug/Treatment

  • Ibrutinib

Outcome

  • N/A

Study Design

  • Safety

  • Observational

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved